Tianjin Tasly Pharma and SemBioSys Genetics of Canada have received business licenses for their Tianjin-based JV, which is based on SemBioSys’ seed-based oilbody and genetic expression technology. Ultimately, the JV expects to use the technology to produce insulin for China and the rest of world. In the near-term, it will develop modernized TCM products and nutraceuticals. After that, the JV will turn its focus toward animal food additives. More details.... Stock Symbols: (SHA: 600535) (TSX: SBS) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});